Google releases TxGemma AI models for drug development

Post Thumbnail

Google has announced the development of an innovative set of “open” AI models called TxGemma, designed to revolutionize the drug development process. The announcement was made on Tuesday during a healthcare-focused event in New York.

According to the company’s statement, the new AI models, which are planned to launch through the Health AI Developer Foundations program this month, have a unique ability to process both regular text and structures of various “therapeutic units,” including chemical compounds, molecules, and proteins.

“Developing therapeutic drugs from concept to approved use is a lengthy and costly process, so we are collaborating with the broader research community to find new ways to improve the efficiency of this process,” explained Karen DeSalvo, Google’s Chief Health Officer, in a blog post provided to TechCrunch. “Researchers will be able to ask TxGemma questions that help predict important properties of potential new therapies, such as their safety or efficacy.”

However, Google has not yet disclosed details about the licensing of these models, leaving open questions about the possibility of their commercial use, customization, and additional training. TechCrunch has reached out to the company for clarification and is awaiting a response.

Despite optimistic statements from many companies, including Google’s spin-off Isomorphic Labs, about the revolutionary potential of AI in drug development, the reality proves to be more complex. Although certain successes have been achieved, artificial intelligence has not yet become a magical solution for laboratory research.

Recent years have been marked by high-profile failures in clinical trials at companies using AI for drug development, including Exscientia and BenevolentAI. Moreover, the accuracy of leading AI systems in this field, such as Google DeepMind’s AlphaFold 3, demonstrates significant variability in results.

AIvengo > Reviews > Google releases TxGemma AI models for drug development
Почитать из последнего
UBTech will send Walker S2 robots to serve on China's border for $37 million
Chinese company UBTech won a contract for $37 million. And will send humanoid robots Walker S2 to serve on China's border with Vietnam. South China Morning Post reports that the robots will interact with tourists and staff, perform logistics operations, inspect cargo and patrol the area. And characteristically — they can independently change their battery.
Anthropic accidentally revealed an internal document about Claude's "soul"
Anthropic accidentally revealed the "soul" of artificial intelligence to a user. And this is not a metaphor. This is a quite specific internal document.
Jensen Huang ordered Nvidia employees to use AI everywhere
Jensen Huang announced total mobilization under the banner of artificial intelligence inside Nvidia. And this is no longer a recommendation. This is a requirement.
AI chatbots generate content that exacerbates eating disorders
A joint study by Stanford University and the Center for Democracy and Technology showed a disturbing picture. Chatbots with artificial intelligence pose a serious risk to people with eating disorders. Scientists warn that neural networks hand out harmful advice about diets. They suggest ways to hide the disorder and generate "inspiring weight loss content" that worsens the problem.
OpenAGI released the Lux model that overtakes Google and OpenAI
Startup OpenAGI released the Lux model for computer control and claims this is a breakthrough. According to benchmarks, the model overtakes analogues from Google, OpenAI and Anthropic by a whole generation. Moreover, it works faster. About 1 second per step instead of 3 seconds for competitors. And 10 times cheaper in cost per processing 1 token.